The role of intraoperative tranexamic acid in transurethral resection of the prostate: a systematic review and meta-analysis of randomised-controlled trials

Cian M. Hehir, Gavin G. Calpin, Gavin P. Dowling, Gordon R. Daly, Barry B. McGuire · 2026

Read The role of intraoperative tranexamic acid in transurethral resection of the prostate: a systematic review and meta-analysis of randomised-controlled trials by Cian M. Hehir, Gavin G. Calpin, Gavin P. Dowling, Gordon R. Daly, Barry B. McGuire (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585812.txt.

Introduction

Cian Hehir and four co-authors pool trials of a clot drug in prostate surgery in a 2026 analysis. The surgery shaves the enlarged prostate through the urethra. Bleeding is its main hazard. Tranexamic acid, a drug that protects clots, might cut that bleeding.

Nine randomized trials with six hundred sixty one patients qualified. Half received the drug during surgery, half did not. The drug group bled about forty milliliters less on average. Their hemoglobin fell less on the first day after surgery. Operations also ran about ten minutes shorter. Clot complications in legs and lungs were checked for safety. The pooled results favor routine use during this surgery. Trial quality limits are noted in the full appraisal.

Catalog record

CREATORCian M. Hehir, Gavin G. Calpin, Gavin P. Dowling, Gordon R. Daly, Barry B. McGuire
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13585812

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The role of intraoperative tranexamic acid in transurethral resection of the prostate: a systematic review and meta-analysis of randomised-controlled trials Authors: Cian M. Hehir, Gavin G. Calpin, Gavin P. Dowling, Gordon R. Daly, Barry B. McGuire Published: 2026 ABSTRACT PurposeTo critically appraise and evaluate the safety and efficacy of intraoperative tranexamic acid (TXA) administration during transurethral resection of the prostate (TURP).MethodsA systematic search of online databases was conducted to identify randomised-controlled trials (RCTs) which compared surgical outcomes and complication rates in patients undergoing TURP for benign prostatic hyperplasia (BPH) who were treated with TXA (intervention) as compared to placebo/none (control). The efficacy of intraoperative TXA was evaluated through outcomes related to blood loss, rate of blood transfusion and operative time. The safety of TXA was evaluated through pooled analysis of both deep venous thrombosis and pulmonary emboli.ResultsNine RCTs met the inclusion criteria for this meta-analysis in which a total of 661 patients underwent TURP for BPH (331 TXA: 330 Control). There was significantly less intraoperative bleeding in the TXA group (MD –40.23 mL [95%CI –66.76 to –13.71], p = 0.003), which was reflected in a significantly lesser haemoglobin drop on the first postoperative day (MD –0.55 g/dL [95%CI –0.71 to –0.39], p < 0.00001). TXA was associated with a significantly shorter operative time (MD –9.77 min [95%CI –16.97 to –2.58], p = 0.008), with patients who received TXA exposed to a significantly reduced risk of blood transfusion (0.99% TXA vs. 7.69% Control, OR 0.16 [95%CI 0.03–0.93], p = 0.04). There was no statistically significant increase in risk of DVT in the TXA group, p = 0.46.ConclusionIntraoperative administration of TXA is safe and effective in reducing intraoperative blood loss, operative time and postoperative haemoglobin (Hb) drop with resultant decrease in blood transfusion requirements. This meta-analysis did not detect any significant increase in venous thrombosis or risk of pulmonary embolism incurred by TXA administration.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11255-026-05180-7. Introduction Benign prostatic hyperplasia (BPH) refers to a non-malignant enlargement of prostatic smooth muscle and epithelial cells, occurring predominantly within the transitional zone and periurethral areas of the prostate gland [1]. The enlargement of periurethral glandular tissue presents commonly with lower urinary tract symptoms (LUTS), and contributes to a significant global disease burden, with 30% of men above 50 years of age suffering from moderate to severe LUTS secondary to BPH [2]. The lifetime global prevalence of BPH is reported at 26.2% and results in significant associated disability as demonstrated by the mean disability adjusted life years (DALYs) of 22.36 years [3, 4]. Although much of the clinical burden of BPH can be managed successfully with conservative measures and pharmacological therapy, surgical intervention will be required in one in five men with BPH [5]. Despite the introduction of numerous novel minimally invasive techniques, TURP remains the reference standard in surgical management of BPH [6]. Even with the significant evolution of operative technologies relevant to TURP in the past decades, bleeding remains a common perioperative complication, especially in the context of an enlarged, congested prostate gland [7]. The advent of bipolar TURP and improved sophistication of endoscopic apparatus has significantly reduced perioperative bleeding and blood transfusion rates [8, 9]. However, intraprocedural blood loss during TURP remains at 2.4–4.6 mL/min [10]. Intraoperative bleeding during TURP can impede endoscopic visualisation, prolong operative time and result in increased patient morbidity [11, 12]. Similarly, bleeding in the postoperative period may result in prolonged bladder irrigation, resultant delays in decatheterisation and discharge, and possibly, albeit uncommon, a return to the operating theatre. As such, limiting blood loss in the context of TURP presents potential to simultaneously improve both patient outcomes and institutional productivity, and is of increased interest in urological literature [13]. Tranexamic acid (TXA) is an antifibrinolytic agent which has shown promising capacity to limit perioperative blood loss across a broad range of surgical interventions [14, 15]. Widespread perioperative use of TXA, however, has been limited by concern surrounding potential for increased risk of thrombotic events. Large scale randomised-controlled trials (RCTs), such as the landmark POISE-3 trial, have demonstrated a 25% reduction in major bleeding events without significant increase in thrombotic complications [16]. A growing body of evidence has been published evaluating the role of intraoperative TXA in TURP. This study aims to critically evaluate the existing evidence base to assess the safety and clinical efficacy of intraoperative TXA in TURP. Methods This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17]. All authors contributed to the formation of the study protocol, which was prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO—CRD42024611563). Population, Intervention, Control, Outcome (PICO) framework Population. Adult, male patients undergoing TURP for BPH. Intervention. Intraoperative administration of tranexamic acid during TURP for BPH. Control. Placebo or no TXA administered during TURP for BPH. Outcome. Primary outcomes include operative time, endoscopic quality of view, intraoperative blood loss, postoperative blood loss, incidence of blood transfusion, and incidence of thrombotic events. Secondary outcomes include time to discontinuation of continuous bladder irrigation, time to decatheterisation, and time to discharge. Search strategy and outcome A systematic search of online electronic databases (PubMed Medline, Scopus & Embase) was performed by two independent reviewers (CMH and GGC). The search terms: (tranexamic acid), (transurethral resection) and (prostate) were combined using the Boolean operator ‘AND’. The search was not limited by year of publication. Duplicate studies were manually removed (CMH) prior to screening of titles, abstracts and full texts. Relevant papers for inclusion were identified using a predetermined search strategy devised by senior author (BBM). Studies were screened for inclusion by two independent reviewers (CMH and GGC) with disagreements resolved through consensus by a third reviewer (BBM). Retrieved studies were reviewed to ensure studies met inclusion criteria for a minimum of one outcome of interest. The reference lists of the included studies were manually screened to identify additional relevant papers for inclusion. The final search was completed on October 5th, 2025. Inclusion criteria Randomised-controlled trials comparing patients undergoing TURP treated with TXA to patients treated with placebo/no TXA.TXA given in the intraoperative period.At least one outcome of interest is reported in both intervention and control groups.Full text available for review in English or French language. Randomised-controlled trials comparing patients undergoing TURP treated with TXA to patients treated with placebo/no TXA. Randomised-controlled trials comparing patients undergoing TURP treated with TXA to patients treated with placebo/no TXA. TXA given in the intraoperative period. TXA given in the intraoperative period. At least one outcome of interest is reported in both intervention and control groups. At least one outcome of interest is reported in both intervention and control groups. Full text available for review in English or French language. Full text available for review in English or French language. Exclusion criteria Non-randomised-controlled trial study design.TXA given in the preoperative or postoperative period only, without intraoperative administration.Inadequate statistical information provided for inclusion in meta-analysis.Full text not available.Published abstracts from conference proceedings, review articles, case reports and editorial articles. Non-randomised-controlled trial study design. Non-randomised-controlled trial study design. TXA given in the preoperative or postoperative period only, without intraoperative administration. TXA given in the preoperative or postoperative period only, without intraoperative administration. Inadequate

Read the complete text